Cortice Biosciences Announces Enrollment Of A Phase 2 Trial Evaluating TPI 287 Plus Avastin® For Treatment Of Recurrent Glioblastoma Naive To Prior Anti-Angiogenic Therapy

Published: Jan 09, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences, Inc. announced today that enrollment has begun in the first stage of a Phase 2 open-label trial designed to evaluate the safety and efficacy of the Company's lead drug candidate, TPI 287, in combination with standard-of-care Avastin® (bevacizumab) for treatment of patients with recurrent glioblastoma (GBM) who have not received prior anti-angiogenic treatment for their disease (clinicaltrials.gov ID: NCT01933815). TPI 287 is an abeotaxane, a novel taxoid derivative that works similarly to taxane chemotherapeutics, such as Taxol®, Abraxane®, and Taxotere®, but with the distinct advantages of being able to circumvent common drug resistance mechanisms and cross the blood-brain barrier.

Help employers find you! Check out all the jobs and post your resume.

Back to news